I
InxMed
Clinical-stage biotech company dedicated to developing innovative, individualized medicines with international impact
About InxMed
InxMed Co., Ltd is a clinical-stage biotechnology company based in Nanjing, China, that focuses on developing innovative therapies to combat drug resistance in hard-to-treat solid tumors. The company operates in the biotechnology and healthcare market, serving clients such as hospitals, healthcare providers, and patients suffering from various types of cancer.
Read full description
InxMed's primary product is Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK). This drug is designed to treat platinum-resistant recurrent ovarian cancer and triple-negative breast cancer. FAK is a protein that, when inhibited, can prevent cancer cells from growing and spreading. In addition to IN10018, InxMed is also developing IN30718, a first-in-class cancer-associated fibroblast (CAF) targeting ADC for high stroma tumors.
The company's business model revolves around the research, development, and commercialization of these innovative cancer therapies. They generate revenue through the sales of their drugs once they have been approved for use by regulatory bodies such as the China National Medical Products Administration (NMPA) and potentially the U.S. Food and Drug Administration (FDA).
InxMed recently raised $50 million in a series B funding round. The funds will be used to support clinical trials of IN-10018 in the U.S. and China, bring more stroma-targeting candidates into clinical trials, and enhance the company's research and development capabilities.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- China
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 70.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning InxMed.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2025 | $34M | $250M | Ennovation Ventures · Fujian Venture Capital · Proxima Ventures · Kunlun Capital | ↗ |
| SERIES BOther financing | May 2022 | $15M | $250M | Hyfinity Investments | ↗ |
Growth signals
Latest recorded traffic for InxMed is 70 monthly website visits, down 56.3% over the last three months. InxMed's team declined 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
China Growth Capital- GCGrand Yangtze Capital
- EVEnnovation Ventures
CS Capital- HBHosenCare Brothers
- ACAIHC Capital
Hyfinity Investments
Series B and later3 investors entered at this stage
- FCFujian Venture Capital
Proxima Ventures
Kunlun Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InxMed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InxMed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.